With $35 Million B Round, Trevena to Push GPCR-Targeted Program into Phase II for Acute Heart Failure
This article was originally published in The Pink Sheet Daily
Executive Summary
Four investors returned to back the Duke University spinout, which is developing biased ligand small molecules.